Back to top
more

Clover Health Investments (CLOV)

(Delayed Data from NSDQ)

$2.78 USD

2.78
7,403,773

-0.11 (-3.81%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $2.81 +0.03 (1.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (63 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 33.33% and 4.78%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates

by Zacks Equity Research

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 0% and 4.52%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CLOV Q3 Estimates Unchanged Before Earnings: How to Play the Stock?

by Zacks Equity Research

The continued strength in Clover Health's offerings is likely to have driven the company's performance in the third quarter.

Zacks Equity Research

10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

10x Genomics (TXG) delivered earnings and revenue surprises of 11.76% and 0.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Clover Health Investments (CLOV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ChromaDex (CDXC) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks Equity Research

Why Fast-paced Mover Clover Health Investments (CLOV) Is a Great Choice for Value Investors

by Zacks Equity Research

Clover Health Investments (CLOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?

by Zacks Equity Research

Here is how Aligos Therapeutics, Inc. (ALGS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks Industry Outlook Highlights Medical Systems, Clover Health Investments and CareCloud

by Zacks Equity Research

Medical Systems, Clover Health Investments and CareCloud are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

Buy These 3 Medical Info Systems Stocks to Capitalize on GenAI Boom

by Urmimala Biswas

Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Clover Health Investments and CareCloud are expected to gain from the GenAI wave.

Zacks Equity Research

Despite Fast-paced Momentum, Clover Health Investments (CLOV) Is Still a Bargain Stock

by Zacks Equity Research

Clover Health Investments (CLOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Clover Health Investments (CLOV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Clover Health Investments (CLOV) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

Clover Health Investments (CLOV) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 125% and 5.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 28.57% and 9.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Enovis (ENOV) Q1 Earnings Match Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 0% and 2.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx (LUNG) delivered earnings and revenue surprises of 16.28% and 7.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

3 Medical Info Systems Stocks to Buy as Industry Rebounds

by Urmimala Biswas

Zacks Medical Info Systems industry stocks like Clover Health Investments (CLOV), Talkspace (TALK) and P3 Health Partners (PIII) are expected to gain from the new normal trends.

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Upgraded to Buy: Here's Why

by Zacks Equity Research

Clover Health Investments, Corp. (CLOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year?

by Zacks Equity Research

Here is how Clover Health Investments, Corp. (CLOV) and Amedisys (AMED) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging Axcella Health (AXLA) This Year?

by Zacks Equity Research

Here is how Axcella Health Inc. (AXLA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year?

by Zacks Equity Research

Here is how Clover Health Investments, Corp. (CLOV) and Axcella Health Inc. (AXLA) have performed compared to their sector so far this year.

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Clover Health Investments, Corp. (CLOV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 53.85% and 1.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nextgen Healthcare (NXGN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 14.29% and 2.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?